491 related articles for article (PubMed ID: 21702914)
21.
Schneider PM; Eshmuminov D; Rordorf T; Vetter D; Veit-Haibach P; Weber A; Bauerfeind P; Samaras P; Lehmann K
BMC Cancer; 2018 May; 18(1):548. PubMed ID: 29743108
[TBL] [Abstract][Full Text] [Related]
22. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma.
Sánchez-Izquierdo N; Perlaza P; Pagès M; Buxó E; Rios J; Rubello D; Colletti PM; Mayoral M; Casanueva S; Fernández-Esparrach G; Ginés A; Fuster D
Clin Nucl Med; 2020 Jan; 45(1):38-43. PubMed ID: 31714278
[TBL] [Abstract][Full Text] [Related]
24. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
25. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
Choi M; Heilbrun LK; Venkatramanamoorthy R; Lawhorn-Crews JM; Zalupski MM; Shields AF
Am J Clin Oncol; 2010 Jun; 33(3):257-61. PubMed ID: 19806035
[TBL] [Abstract][Full Text] [Related]
26. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
[TBL] [Abstract][Full Text] [Related]
29. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.
Konski A; Li T; Sigurdson E; Cohen SJ; Small W; Spies S; Yu JQ; Wahl A; Stryker S; Meropol NJ
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):55-9. PubMed ID: 19004571
[TBL] [Abstract][Full Text] [Related]
30. PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study.
Obermannova R; Selingerova I; Rehak Z; Jedlicka V; Slavik M; Fabian P; Novotny I; Zemanova M; Studentova H; Grell P; Zdrazilova Dubska L; Demlova R; Harustiak T; Hejnova R; Kiss I; Vyzula R
Ther Adv Med Oncol; 2021; 13():17588359211065153. PubMed ID: 35035533
[TBL] [Abstract][Full Text] [Related]
31. Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.
Schmidt M; Bollschweiler E; Dietlein M; Mönig SP; Kobe C; Vallböhmer D; Eschner W; Hölscher A; Schicha H
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):735-44. PubMed ID: 19096843
[TBL] [Abstract][Full Text] [Related]
32. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
33. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Goodman KA; Ou FS; Hall NC; Bekaii-Saab T; Fruth B; Twohy E; Meyers MO; Boffa DJ; Mitchell K; Frankel WL; Niedzwiecki D; Noonan A; Janjigian YY; Thurmes PJ; Venook AP; Meyerhardt JA; O'Reilly EM; Ilson DH
J Clin Oncol; 2021 Sep; 39(25):2803-2815. PubMed ID: 34077237
[TBL] [Abstract][Full Text] [Related]
34. Prognostic role of early 18-FDG PET/CT during neoadjuvant chemotherapy for resectable adenocarcinoma of the esophagus and esophagogastric junction.
Harustiak T; Zemanova M; Fencl P; Pazdro A; Snajdauf M; Faltova H; Lischke R; Stolz AJ
Neoplasma; 2021 Mar; 68(2):423-433. PubMed ID: 33440988
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
Song SY; Kim JH; Ryu JS; Lee GH; Kim SB; Park SI; Song HY; Cho KJ; Ahn SD; Lee SW; Shin SS; Choi EK
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1053-9. PubMed ID: 15964705
[TBL] [Abstract][Full Text] [Related]
36. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study.
Goldberg N; Kundel Y; Purim O; Bernstine H; Gordon N; Morgenstern S; Idelevich E; Wasserberg N; Sulkes A; Groshar D; Brenner B
Radiat Oncol; 2012 Aug; 7():124. PubMed ID: 22853868
[TBL] [Abstract][Full Text] [Related]
37. [Importance of PET in surgery of esophageal cancer].
Ott K; Schmidt T; Lordick F; Herrmann K
Chirurg; 2014 Jun; 85(6):505-12. PubMed ID: 24817185
[TBL] [Abstract][Full Text] [Related]
38. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.
Moehler M; Gockel I; Roessler HP; Arnold D; Trarbach T; Thomaidis T; Klautke G; Rödel C; Brenner B; Lang H; Galle PR; Schimanski CC; Schmidberger H
BMC Cancer; 2013 Feb; 13():75. PubMed ID: 23394629
[TBL] [Abstract][Full Text] [Related]
39. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer.
Ott K; Herrmann K; Schuster T; Langer R; Becker K; Wieder HA; Wester HJ; Siewert JR; zum Büschenfelde CM; Buck AK; Wilhelm D; Ebert MP; Peschel C; Schwaiger M; Lordick F; Krause BJ
Ann Surg Oncol; 2011 Nov; 18(12):3316-23. PubMed ID: 21537865
[TBL] [Abstract][Full Text] [Related]
40. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
